Loomis Sayles & CO L P Horizon Therapeutics Public LTD CO Transaction History

Loomis Sayles & CO L P

$70.3 Billion
Q1 2024

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$58.92 - $84.67 $15.1 Million - $21.6 Million	-255,525 Reduced 98.61%	3,591 $222,000
Q2 2022 Aug 05, 2022	SELL	$79.4 - $116.36 $7.18 Million - $10.5 Million	-90,470 Reduced 25.88%	259,116 $20.7 Million
Q1 2022 May 13, 2022	BUY	$86.42 - $109.81 $955,286 - $1.21 Million	11,054 Added 3.27%	349,586 $36.8 Million
Q4 2021 Feb 14, 2022	SELL	$98.56 - $119.91 $338,356 - $411,651	-3,433 Reduced 1.0%	338,532 $36.5 Million
Q3 2021 Nov 12, 2021	BUY	$91.91 - $110.37 $894,284 - $1.07 Million	9,730 Added 2.93%	341,965 $37.5 Million

Q2 2021 Aug 13, 2021	BUY	$86.24 - $95.92 $1.08 Million - $1.2 Million	12,508 Added 3.91%	332,235 $31.1 Million
Q1 2021 May 17, 2021	SELL	$71.83 - $95.48 $1.31 Million - $1.73 Million	-18,168 Reduced 5.38%	319,727 $29.4 Million
Q4 2020 Feb 12, 2021	SELL	$67.0 - $84.39 $117,384 - $147,851	-1,752 Reduced 0.52%	337,895 $24.7 Million
Q3 2020 Nov 12, 2020	SELL	$55.23 - $79.93 $8.39 Million - $12.1 Million	-151,904 Reduced 30.9%	339,647 $26.4 Million
Q2 2020 Aug 14, 2020	SELL	$30.2 - $56.98 $27.6 Million - $52 Million	-912,729 Reduced 65.0%	491,551 $27.3 Million
Q1 2020 May 15, 2020	BUY	$24.87 - $38.56 $21,189 - $32,853	852 Added 0.06%	1,404,280 $41.6 Million
Q4 2019 Feb 14, 2020	SELL	$25.43 - $36.67 $959,575 - $1.38 Million	-37,734 Reduced 2.62%	1,403,428 $50.8 Million
Q3 2019 Nov 13, 2019	BUY	$23.0 - $27.97 $5.88 Million - $7.15 Million	255,461 Added 21.55%	1,441,162 $39.2 Million
Q2 2019 Aug 14, 2019	BUY	$22.81 - $28.48 $27 Million - $33.8 Million	1,185,701 New	1,185,701 $28.5 Million

Others Institutions Holding HZNP

# of Institutions

Shares Held

2.07M

Call Options Held

Put Options Held

20K

View Full List

About Horizon Therapeutics Public Ltd Co

Ticker HZNP
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 230,384,000
Description
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines ...

More about HZNP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Loomis Sayles & CO L P, based on Form 13F filings with the SEC.

News

Stay updated on Loomis Sayles & CO L P with notifications on news.

Account